Net Loss per Share Attributable To Common Stockholders

9 Months Ended

Sep. 30, 2025

Net Loss per Share Attributable To Common Stockholders [Abstract]

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

8. net loss per share attributable to common stockholders

Basic and diluted net loss per share was calculated as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Numerator:
Net loss attributable to common stockholders	$	(1,904,184	)	$	(666,442	)	$	(3,473,150	)	$	(1,445,285	)
Denominator:
Weighted-average common shares outstanding, basic and diluted		27,975,207			26,645,835			27,479,246			26,546,840
Net loss per share attributable to common stockholders, basic and diluted	$	(0.07	)	$	(0.03	)	$	(0.13	)	$	(0.05	)

Our potentially dilutive securities, which include or have included outstanding stock options and certain warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

We excluded the following from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:

	As at September 30,
	2025		2024
Outstanding options under the Company’s Amended and Restated 2018 Stock Option Plan		1,508,934		1,508,934
Outstanding options under the Company’s 2024 Stock Option Plan		222,984		-
Outstanding 2022 warrants		40,124		40,124
Outstanding 2018 warrants		-		47,620
		1,772,042		1,596,678

Turn Therapeutics Inc. 10-Q